Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Tan, Ying ^a   Song, Di ^a   Wu, Li Hua ^a,b   Yu, Feng ^a   Zhao, Ming Hui ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

Anti C1q autoantibodies; C1q depostion; Lupus nephritis; Serum levels of C1q

Indexed keywords

AUTOANTIBODY; COMPLEMENT COMPONENT C1Q; CREATININE; IMMUNOGLOBULIN G; PROTEIN ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SLEDAI;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; COMPLEMENT C1Q; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MALE; YOUNG ADULT;

EID: 84875036235     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-63     Document Type: Article

References (31)

1. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Medicine (Baltimore) 2003 82 299 308 10.1097/01.md.0000091181.93122.55
2. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Son M, Santiago-Schwarz F, Al-Abed Y, Diamond B, Proc Natl Acad Sci U S A 2012 109 3160 E3167 10.1073/pnas.1212753109 23093673
3. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Lood C, Gullstrand B, Truedsson L, Olin AI, Alm GV, Ronnblom L, Sturfelt G, Eloranta ML, Bengtsson AA, Arthritis Rheum 2009 60 3081 3090 10.1002/art.24852 19790049
4. Complement, interferon and lupus. Elkon KB, Santer DM, Curr Opin Immunol 2012 24 665 670 10.1016/j.coi.2012.08.004 22999705
5. Pediatric systemic lupus erythematosus with C1q deficiency. Kallel-Sellami M, Baili-Klila L, Zerzeri Y, Laadhar L, Blouin J, Abdelmoula MS, Zitouni M, Fremeaux-Bacchi V, Ben Dridi MF, Makni S, Ann N Y Acad Sci 2007 1108 193 196 10.1196/annals.1422.021 17893985
6. Differences among immune complexes: association of C1q in SLE immune complexes with renal disease. Greisman SG, Redecha PB, Kimberly RP, Christian CL, J Immunol 1987 138 739 745 3492531
7. Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Fang QY, Yu F, Tan Y, Xu LX, Wu LH, Liu G, Shao FM, Zhao MH, Nephrol Dial Transplant 2009 24 172 178 18697800
8. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA, Ann Rheum Dis 2005 64 444 448 15286009
9. Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Trouw LA, Seelen MA, Duijs JM, Benediktsson H, Van Kooten C, Daha MR, Clin Exp Immunol 2003 132 32 39 10.1046/j.1365-2249.2003.02108.x 12653833
10. Immune deposition of C1q and anti-C1q antibodies in the kidney is dependent on the presence of glomerular IgG. Trouw LA, Duijs JM, van Kooten C, Daha MR, Mol Immunol 2003 40 595 602 10.1016/j.molimm.2003.08.003 14597162
11. Anti-C1q autoantibodies in murine lupus nephritis. Trouw LA, Seelen MA, Visseren R, Duijs JM, Benediktsson H, de Heer E, Roos A, van Kooten C, Daha MR, Clin Exp Immunol 2004 135 41 48 10.1111/j.1365-2249.2004.02345.x 14678263
12. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA, Kishore U, Salant DJ, Verbeek JS, van Kooten C, Daha MR, J Clin Invest 2004 114 679 688 15343386
13. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Hochberg MC, Arthritis Rheum 1997 40 1725 9324033
14. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Arthritis Rheum 1992 35 630 640 10.1002/art.1780350606 1599520
15. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH, Kidney Int 2009 76 307 317 10.1038/ki.2009.136 19404274
16. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, J Am Soc Nephrol 2004 15 241 250 10.1097/01.ASN.0000108969.21691.5D 14747370
17. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE, Kidney Int 1984 25 689 695 10.1038/ki.1984.75 6482173
18. Alternative complement pathway deregulation is correlated with dengue severity. Nascimento EJ, Silva AM, Cordeiro MT, Brito CA, Gil LH, Braga-Neto U, Marques ET, PLoS One 2009 4 6782 10.1371/journal.pone.0006782 19707565
19. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Katsumata Y, Miyake K, Kawaguchi Y, Okamoto Y, Kawamoto M, Gono T, Baba S, Hara M, Yamanaka H, Arthritis Rheum 2011 63 2436 2444 10.1002/art.30401 21506094
20. C1q complement component and -antibodies reflect SLE activity and kidney involvement. Horak P, Hermanova Z, Zadrazil J, Ciferska H, Ordeltova M, Kusa L, Zurek M, Tichy T, Clin Rheumatol 2006 25 532 536 10.1007/s10067-005-0110-4 16311713
21. Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis. Chen Z, Wang GS, Wang GH, Li XP, Clin Rheumatol 2012 31 1323 1329 10.1007/s10067-012-2017-1 22696012
22. Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q. Uwatoko S, Mannik M, J Clin Invest 1988 82 816 824 10.1172/JCI113684 3262124
23. Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Bulla R, Agostinis C, Bossi F, Rizzi L, Debeus A, Tripodo C, Radillo O, De Seta F, Ghebrehiwet B, Tedesco F, Mol Immunol 2008 45 2629 2640 10.1016/j.molimm.2007. 12.025 18295334
24. The C1q family of proteins: insights into the emerging non-traditional functions. Ghebrehiwet B, Hosszu KK, Valentino A, Peerschke EI, Front Immunol 2012 3 52 22536204
25. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. Nauta AJ, Castellano G, Xu W, Woltman AM, Borrias MC, Daha MR, van Kooten C, Roos A, J Immunol 2004 173 3044 3050 15322164
26. Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice. Krishnan MR, Wang C, Marion TN, Kidney Int 2012 82 184 192 10.1038/ki.2011.484 22297676
27. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Sjowall C, Zickert A, Skogh T, Wettero J, Gunnarsson I, Arthritis Res Ther 2009 11 188 10.1186/ar2880 20003354
28. SLE diagnosis and treatment: when early is early. Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L, Rampudda M, Ghirardello A, Iaccarino L, Autoimmun Rev 2010 10 55 60 10.1016/j.autrev.2010.08.014 20813207
29. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ, Gingras AR, Tzima S, Vivanco F, Egido J, Eur J Immunol 2003 33 465 473 10.1002/immu.200310022 12645945
30. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Tan Y, Yu F, Qu Z, Su T, Xing GQ, Wu LH, Wang FM, Liu G, Yang L, Zhao MH, Clin J Am Soc Nephrol 2011 6 93 100 10.2215/CJN.09051209 20813859
31. Pentraxins, humoral innate immunity and tissue injury. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A, Curr Opin Immunol 2008 20 538 544 10.1016/j.coi.2008.05.004 18579363